DENERVACIJA BUBREŽNIH ARTERIJA I REZISTENTNA HIPERTENZIJA by INGRID PRKAČIN et al.
41
Acta Med Croatica, Vol. 70 (2016) (Suppl. 2) 41-45  Professional Paper
RENAL DENERVATION AND RESISTANT HYPERTENSION:
BACK TO THE FUTURE
INGRID PRKAčIN1,2, BORNA VRHOVEC1, ANA LEGOVIć1, VESNA đERMANOVIć DOBROTA2, 
TOMISLAV BuLuM2 and VINKO VIDJAK2,3
1University of Zagreb, School of Medicine, Merkur University Hospital,
Department of Internal Medicine, 2University of Zagreb, School of Medicine,
Merkur University Hospital, Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, 
3University of Zagreb, School of Medicine, Merkur University Hospital, Department of Radiology,
Zagreb, Croatia 
Renal sympathetic denervation (RDN) with radiofrequency (RF) is being used to treat resistant hypertension 
in seven non-responder patients (62±6 years for age, 5F/2M) despite treatment with >4 different antihyper-
tensive drugs in optimal doses. Prior to diagnosing a patient as having resistant hypertension, we document 
adherence and exclude white-coat hypertension, inaccurate measurement of blood pressure and second-
ary causes. Office blood pressure (BP) measurements at 1, 3, 6, 12 and 18 months follow-up visits were 
compared to baseline. We used STATISTICA 10, 2011 software (Stat Soft Inc., Tulsa, OK, USA).  Values are 
mean SD and considered statistically significant if P <0.001. At baseline, values were 184±21 and 106±26 
mmHg for systolic (SBP) and diastolic (DBP),  6.7±1 for number of antihypertensive drug classes.  One, 3, 
6, 12 and 18 months after RDN, office SBP values were significantly lower (144±13 mmHg, 140±17, 141± 
15, 139±12 and 135±11 mmHg; P <0.001), with no significant reduction in DBP values at 1, 3, 6, 12 and 18 
months after RDN (81±6, 82±9, 79±9, 78±6, and 76±7 mmHg). The number of antihypertensive drug classes 
before and 6, 12, 18 months after RDN were evaluated.  Six months after RDN the number of antihyperten-
sive drug classes required was 6.5±1, after 12 and 18 months was 5.5±1 and 4.5±1.  During RDA no compli-
cations occurred  (the pain during the procedure was well tolerated) and the renal function remained stabile. 
Renal sympathetic denervation is being a concomitant treatment of drug-resistant hypertension (rHT). The 
sustained reduction of SBP was observed after the RDN. Patients have benefit the most from procedure 
after 6-12 months. Further meta-analysis will evaluate the importance of new devices for less pain treatment 
of RDN. 
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INTRODuCTION
If pharmacological therapy with at least three antihy-
pertensive drugs in optimal doses, including a diu-
retic, fails to reduce the office blood pressure to below 
140/90mmHg, patients are considered to suffer from 
drug resistant hypertension (rHT)(1,2).  The prevalence of 
rHT has been estimated between 8 to 13% of all anti-
hypertensive drug treated patients(2). In recent decades, 
the use of antihypertensive drugs has revolutionised the 
therapy of hypertension. Despite the available pharma-
cological inhibition of the sympathetic nervous system, 
about 50% of patients show suboptimal control and 
pharmacotherapy does not provide adequate effects in 
clinical practice(3-5). Although the most common causes 
of therapeutic failure are undiscovered secondary causes 
of hypertension and lack of patient/doctors compliance, 
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in about 10% of cases it can be attributed to resistant 
hypertension caused by a hyperactivity of the sympa-
thetic nervous system,condition that confers a high car-
diovascular risk to the patient(6,7,8).  Renal sympathetic 
denervation (RDN) produce multilevel inhibition of the 
sympathetic nervous system, and trigers additional posi-
tive metabolic effects(9,10,11). 
The reason for the rapid introduction of RDN in the 
therapy of rHT were the reported high efficiency and 
safety of the procedure(9). The effectiveness was dem-
onstrated in the studies Symplicity HTN-1 and HTN-2, 
and in the EnligHTN-1 Study (by using special RF abla-
tion catheters)(10,11). According to the results of different 
trials, including Symplicity HTN-3 (this study did not 
show differences in SBP reduction between treatment 
and control groups, but in the context of the study char-
acteristics and the way it was conducted, there are sev-
eral concerns about inexperienced doctors in the field of 
RDN, the study population and the medical treatment), 
RDN seems to be safe and procedure-related complica-
tions of catheter-based RDN were rare(11,12). 
Based on these findings the objective of this study was 
to investigate long term effects of RDN on BP control 
and renal function parameters in our patients. 
SuBJECTS, MATERIALS AND METHODS
Study included 7 patients with proven resistant hyper-
tension (rHT) from a cohort of 101 patients referred to 
ambulance due to suspected rHT. Prior to diagnosing 
a patient as having rHT, we document adherence and 
exclude white-coat hypertension, inaccurate measure-
ment of blood pressure and secondary causes.  In order 
to qualify patients as rHT (defined as BP that remains 
>140/90 mmHg in spite of the use of >4 different anti-
hypertensive agents in optimal dose, including diuretic, 
and lifestyle changes), patients for RDN had to show a 
mean systolic BP >150 mmHg in the 24 hr ambulatory 
blood pressure measurement (ABPM).
Data collection 
Basic anthropometric measurements were performed on 
all subjects. Office Blood pressure was measured twice 
in the sitting position with a mercury sphygmomanom-
eter after a resting period of 5-10 minutes. Fasting ve-
nous blood samples were collected in the morning be-
tween 08:00 and 09:30 hours after an overnight fast for 
the determination of basic blood chemistries. Data on 
serum creatinine levels, age, sex and race were used to 
calculate the estimated GFR using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) formu-
la, which has been shown to be accurate in determining 
kidney function in rHT(6). 
Study procedure
In our Center RDN was performed using standard radi-
ofrequency system with ablation catheter (5F system/ 6F 
guide catheter; Symplicity TM RDN System) inserted 
through the femoral artery, engaging the renal artery 
bilaterally. Five to six nerve ablations of 100 second du-
ration on each side were performed without any compli-
cations.  During the RDN patients received intravenous 
narcotic and sedative drugs agains the abdominal pain.
Office BP measurements at 1, 3, 6, 12 and 18 months 
follow-up visits were compared to baseline. At six 
months after RDN duplex sonography was performed. 
The number of antihypertensive drug classes before and 
6, 12, 18 months after RDN were evaluated.
The study protocol complies with the Declaration of 
Helsinki as well as with local institutional guidelines, 
and was approved by the local ethics committees.  
Statistical Analysis 
Data are expressed as means ± SD for normally distrib-
uted values, as median with range for non-normally dis-
tributed values, and percentage. 
Level of statistical significance was considered statis-
tically significant if P <0.001. Statistical analysis was 
performed by statistical package STATISTICA 10, 2011 
software (Stat Soft Inc., Tulsa, OK, uSA). 
RESuLTS
Purpose of this Study was to evaluate efficacy and 
safety of renal sympathetic denervation (RDN) with 
radiofrequency (RF) as additional therapy for rHT pt 
during the 18-month follow-up.  RDN is being used to 
treat rHT in seven non-drug responder patients (62±6 
years for age, two male) with >4 different antihyper-
tensive drugs in optimal doses, with a severe comorbid-
ity (four patients (2F/2M) with well controled diabetes 
mellitus type 2, one male patient with coronary artery 
disease, two male patients with chronic kidney disease 
(defined as eGFR CKD EPI <60 ml/min/1.73m2). At 
baseline, before RDN, values were 184±21 and 106±26 
mmHg for systolic (SBP) and diastolic (DBP), heart 
rate 67±6 beats/min, 6.7±1 for number of different anti-
hypertensive drug classes.  One, 3, 6, 12 and 18 months 
after RDN, office SBP values were significantly lower 
(144±13, 140±17, 141±15, 139±12 and 135±11 mmHg; P 
<0.001), with no significant reduction in DBP values at 
1, 3, 6, 12 and 18 months after RDN (81±6, 82±9, 79±9, 
78±6, and 76±7 mmHg).
The characteristics of the study subjects are listed in Table 1. 
During RDA no complications occurred  (the pain dur-
ing the procedure was well tolerated) and the mean re-
nal function at baseline was eGFR CKD-EPI stage G2 
(65±38 ml/min/1.73m2).  
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Table 1.
Baseline clinical characteristics and biochemical mea-






Age (yrs) 62 ± 6 
Women 5/7 
Type 2 diabetes 4/7 
Body mass index (kg/m2) 32± 2 
Antihypertensive drugs (n) 6.7 ± 1 
ACEI 2/7 
ARB 5/7 
ACEI and ARB 0/7 
β - blocker 5/7 
Calcium-channel blocker 7/7 
α - blockers 5/7 
Diuretic 7/7 
Direct renin inhibitor 0/7 
Vasodilator 2/7 
Central acting sympatholytic 7/7 
Office SBP (mmHg) 184 ± 21 
Office DBP (mmHg) 106 ± 26 
Heart rate (beats/min) 67 ± 6 
eGFR (ml/min per 1.73m2) 65 ± 38 








All patients show a small reduction of the mean ABPM 
but not show a reduction of systolic BP >10 mmHg  at 6 
months following RDN therapy. 
Six months after RDN the number of antihypertensive 
drug classes required was 6.5±1, after 12 and 18 months 
was 5.5±1 and 4.5±1.  Values of HbA1c were stabile be-
fore and (6.5-7.1 and 6.7-7.0%) after RDN on oral hy-
poglicemic drugs in 50% of patients.
At six months duplex sonography was performed in all 
patients (to exclude renal artery stenosis after RDN). We 
did not observe any renal vascular complications during 
the 18 months of follow up. The renal function remained 
stabile during 18-month follow up with mean eGFR 
CKD-EPI stage G2 (61±36 ml/min/1.73m2).
DISCuSSION
The resistant hypertension treatment is achieved with 
nonpharmacological and pharmacological approach, 
treating secondary hypertension causes and invasive 
procedures such as RDN(1). Many observational stud-
ies and our results have shown that RDN is a safe and 
effective method of reducing office BP in patients with 
rHT, with an additional positive effect on blood glucose 
metabolism, obstructive sleep apnea and signs of hyper-
tensive end organ damage(2-4). In support of these data, 
we documented that RDN was associated with good re-
sponse in SBP regulation and improved stabile kidney 
function after RDN without complications such as renal 
stenosis or a pseudoaneurysm of the femoral artery after 
the procedure. 
It is very important to select patients most likely to have 
benefit from invasive procedures such as RDN, because 
patients with rHT represent a very mixed group of di-
agnoses(5). Chronic kidney disease (CKD) patients have 
sympathetic nervous system hyperactivation that leads 
to fluid overload, aggravation of hypertension and fur-
ther deterioration and loss of renal function, and it has 
been demonstrated that RDN is associated with stabile 
kidney function(5). The most obvious explanation relating 
effect of stabile kidney function could be that after RDN 
treatment increase renal blood flow which result in in-
crease in GFR. Studies that have measured kidney func-
tion in pt with rHT with gold standard methods (CKD-
EPI, MDRD) also found high prevalence of CKD in  rHT 
patients(6-8). Our results support these observations, we 
also found mean eGFR CKD-EPI stage G2 (65±38 ml/
min/1.73m2) on beginning, and after 18-month follow up 
eGFR was stabile.
The present study has a number of potential limitations. 
First, our study is obviously limited by the small number 
of patients. Furthermore our analyses were based on 
measurement of office blood pressure and we did not 
have performed ABPM in all patients in 12/18-month 
follow up. 
To the best of our knowledge, this is the first report of 
beneficial RDN treatment for 18-month follow up in 
rHT patients in Croatia. However, our data show addi-
tional effect of treatmen in slowing natural progression 
of CKD.
In this study RDN with radiofrequency (RF)  ablation 
is being used to treat rHT, with good safety profil and 
no complications occurred, the pain during the proce-
dure was well tolerated. From other studies as 15-13% of 
treated patients are non-responders to RDN with radiof-
requency, option is to repeat RF or perform RDN with 
cryoenergy as second line option(9).
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CONCLuSIONS
Our results suggest that sustained reduction of SBP after 
the RDN was observed in 18-month follow-up. 
Renal sympathetic denervation is being a concomitant 
treatment of drug-resistant hypertension (rHT).  High 
risk patients with resistant hypertension have benefit the 
most from procedure after 6-12 months. Further meta-
analysis will evaluate the optimal target population and 
importance of RDN as rHT treatment. 
The future of the RDN systems are noninvasive, de-
livering externally focused ultrasound energy to the 
renal nerves using Doppler-based ultrasound image 
guidance to track and correct for renal artery motion 
during treatment.
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Denervacija bubrežnih arterija (DBA) radiofrekvencijom jedna je od obećavajućih novih metoda liječenja 
rezistentne hipertenzije refraktorne (RH) na optimalno liječenje kombiniranom antihipertenzivnom terapijom 
koja uključuje 3 i više lijekova iz različitih antihipertenzivnih skupina od kojih jedan mora biti diuretik. Nakon 
isključenja sekundarnih uzroka, neadekvatnog mjerenja tlaka te nesuradljivosti prikazujemo učinak DBA u 
7 bolesnika (62±6 years for age, 5F/2M) tijekom razdoblja od 18 mjeseci praćenja.  Za statističku analizu 
korišten je program STATISTICA 10, 2011 softwer (Stat Soft Inc., Tulsa, OK, USA), uz razinu značajnosti
P <0,001.
Bolesnici su praćeni  na redovitim ambulantnim kontrolama 1, 3, 6, 12 i 18 mjeseci nakon DBA uz mjere-
nje krvnog tlaka i praćenje laboratorijskih parametara. Od početnih izmjerenih vrijednosti tlaka u ambulanti 
184±21 za sistolički i 106±26 mm Hg za dijastolički tlak, uz prosječni broj antihipertenzivnih lijekova od  6,7±1 
nakon DBA 1, 3, 6, 12  i 18 mjeseci prati se značajno smanjenje sistoličkih vrijednosti tlaka  (144±13, 140±17, 
141±15, 139±12, 135±11 mm Hg; P <0,001), bez značajnog smanjenja dijastoličkih vrijednosti (81±6, 82±9, 
79±9, 78±6, 76±7 mmHg). Nakon 6 mjeseci prosječan broj antihipertenzivnih lijekova ostao je nepromijenjen 
(važno da se objektivizira učinak DBA) i iznosio je 6.5±1, dok je nakon 12 i 18 mjeseci došlo do smanjenja 
broja antihipertenzivnih lijekova (5.5±1 i 4.5±1). Tijekom DBA bolest je bila podnošljiva, nije zabilježeno ne-
posrednih ni kasnijih komplikacija DBA, bubrežna funkcija je bila stabilna tijekom praćenja. Dokazana je du-
goročna sigurnost DBA i učinkovitost na smanjenje sistoličkog krvnog tlaka u bolesnika s refraktornom RH.
Ključne riječi:  denervacija bubrežnih arterija, hipertenzija
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